The University of Chicago Header Logo

Connection

Gregory Karczmar to Female

Back to Details
This is a "connection" page, showing publications Gregory Karczmar has written about Female.
Gregory Karczmar
Connection Strength
1.005
Female
  1. K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy. J Appl Clin Med Phys. 2026 Jan; 27(1):e70439.
    View in: PubMed
    Score: 0.045
  2. Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 12; 104:9-15.
    View in: PubMed
    Score: 0.038
  3. Pharmacokinetic Analysis of Enhancement-Constrained Acceleration (ECA) reconstruction-based high temporal resolution breast DCE-MRI. PLoS One. 2023; 18(6):e0286123.
    View in: PubMed
    Score: 0.038
  4. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Acad Radiol. 2022 10; 29(10):1469-1479.
    View in: PubMed
    Score: 0.035
  5. Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent. Phys Med. 2021 Jan; 81:31-39.
    View in: PubMed
    Score: 0.032
  6. Magnetic resonance angiography reveals increased arterial blood supply and tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer. NMR Biomed. 2020 10; 33(10):e4363.
    View in: PubMed
    Score: 0.031
  7. Low-dose imaging technique (LITE) MRI: initial experience in breast imaging. Br J Radiol. 2019 Nov; 92(1103):20190302.
    View in: PubMed
    Score: 0.029
  8. Magnetic resonance spectroscopy detects differential lipid composition in mammary glands on low fat, high animal fat versus high fructose diets. PLoS One. 2018; 13(1):e0190929.
    View in: PubMed
    Score: 0.026
  9. MRI reveals increased tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer. NMR Biomed. 2017 Oct; 30(10).
    View in: PubMed
    Score: 0.025
  10. MRI ductography of contrast agent distribution and leakage in normal mouse mammary ducts and ducts with in situ cancer. Magn Reson Imaging. 2017 07; 40:48-52.
    View in: PubMed
    Score: 0.025
  11. Fast bilateral breast coverage with high spectral and spatial resolution (HiSS) MRI at 3T. J Magn Reson Imaging. 2017 11; 46(5):1341-1348.
    View in: PubMed
    Score: 0.025
  12. Kinetic Analysis of Benign and Malignant Breast Lesions With Ultrafast Dynamic Contrast-Enhanced MRI: Comparison With Standard Kinetic Assessment. AJR Am J Roentgenol. 2016 Nov; 207(5):1159-1166.
    View in: PubMed
    Score: 0.024
  13. Ultrafast Bilateral DCE-MRI of the Breast with Conventional Fourier Sampling: Preliminary Evaluation of Semi-quantitative Analysis. Acad Radiol. 2016 09; 23(9):1137-44.
    View in: PubMed
    Score: 0.023
  14. Correlation of In Vivo and Ex Vivo ADC and T2 of In Situ and Invasive Murine Mammary Cancers. PLoS One. 2015; 10(7):e0129212.
    View in: PubMed
    Score: 0.022
  15. MRI accurately identifies early murine mammary cancers and reliably differentiates between in situ and invasive cancer: correlation of MRI with histology. NMR Biomed. 2015 Sep; 28(9):1078-86.
    View in: PubMed
    Score: 0.022
  16. B1 and T1 mapping of the breast with a reference tissue method. Magn Reson Med. 2016 Apr; 75(4):1565-73.
    View in: PubMed
    Score: 0.022
  17. Comparison of dynamic contrast-enhanced MRI parameters of breast lesions at 1.5 and 3.0?T: a pilot study. Br J Radiol. 2015 May; 88(1049):20150021.
    View in: PubMed
    Score: 0.021
  18. X-ray fluorescence microscopy demonstrates preferential accumulation of a vanadium-based magnetic resonance imaging contrast agent in murine colonic tumors. Mol Imaging. 2015; 14.
    View in: PubMed
    Score: 0.021
  19. Mammary cancer initiation and progression studied with magnetic resonance imaging. Breast Cancer Res. 2014 Dec 16; 16(6):495.
    View in: PubMed
    Score: 0.021
  20. High resolution 3D MRI of mouse mammary glands with intra-ductal injection of contrast media. Magn Reson Imaging. 2015 Jan; 33(1):161-5.
    View in: PubMed
    Score: 0.021
  21. Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed. 2013 May; 26(5):569-77.
    View in: PubMed
    Score: 0.018
  22. T(2)* relaxation times of intraductal murine mammary cancer, invasive mammary cancer, and normal mammary gland. Med Phys. 2012 Mar; 39(3):1309-13.
    View in: PubMed
    Score: 0.017
  23. Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol. 2011 Dec; 18(12):1467-74.
    View in: PubMed
    Score: 0.017
  24. In vivo MRI of early stage mammary cancers and the normal mouse mammary gland. NMR Biomed. 2011 Aug; 24(7):880-7.
    View in: PubMed
    Score: 0.016
  25. Echo-planar spectroscopic imaging (EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE). Magn Reson Med. 2010 Jun; 63(6):1557-63.
    View in: PubMed
    Score: 0.015
  26. Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology. 2009 Nov; 253(2):399-406.
    View in: PubMed
    Score: 0.015
  27. Fourier component imaging of water resonance in the human breast provides markers for malignancy. Phys Med Biol. 2009 Oct 07; 54(19):5767-79.
    View in: PubMed
    Score: 0.015
  28. Clinical implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve unilateral full-breast coverage. Magn Reson Imaging. 2010 Jan; 28(1):16-21.
    View in: PubMed
    Score: 0.014
  29. Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study. Breast Cancer Res. 2009; 11(5):R65.
    View in: PubMed
    Score: 0.014
  30. Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. Radiology. 2007 Dec; 245(3):684-91.
    View in: PubMed
    Score: 0.013
  31. Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging. 2006 Dec; 24(6):1311-5.
    View in: PubMed
    Score: 0.012
  32. High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol. 2006 Jan; 186(1):30-7.
    View in: PubMed
    Score: 0.011
  33. A Translational Research Leveraging Diagnostic Accuracy of Innovations in MRI as a Model for Early Breast Cancer Detection in Uganda. Technol Cancer Res Treat. 2025 Jan-Dec; 24:15330338251356549.
    View in: PubMed
    Score: 0.011
  34. Fourier components of inhomogeneously broadened water resonances in breast: a new source of MRI contrast. Magn Reson Med. 2004 Jul; 52(1):193-6.
    View in: PubMed
    Score: 0.010
  35. The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging. 2003 Oct; 18(4):442-8.
    View in: PubMed
    Score: 0.010
  36. Towards Patient-Specific Optimization of Neoadjuvant Treatment Protocols for Breast Cancer Based on Image-Guided Fluid Dynamics. IEEE Trans Biomed Eng. 2022 11; 69(11):3334-3344.
    View in: PubMed
    Score: 0.009
  37. Safely reducing unnecessary benign breast biopsies by applying non-mass and DWI directional variance filters to ADC thresholding. BMC Med Imaging. 2022 09 29; 22(1):171.
    View in: PubMed
    Score: 0.009
  38. Breast MR imaging with high spectral and spatial resolutions: preliminary experience. Radiology. 2002 Aug; 224(2):577-85.
    View in: PubMed
    Score: 0.009
  39. Spectrally inhomogeneous effects of contrast agents in breast lesion detected by high spectral and spatial resolution MRI. Acad Radiol. 2002 Aug; 9 Suppl 2:S352-4.
    View in: PubMed
    Score: 0.009
  40. Enhancement-constrained acceleration: A robust reconstruction framework in breast DCE-MRI. PLoS One. 2021; 16(10):e0258621.
    View in: PubMed
    Score: 0.008
  41. Robustness of radiomic features of benign breast lesions and hormone receptor positive/HER2-negative cancers across DCE-MR magnet strengths. Magn Reson Imaging. 2021 10; 82:111-121.
    View in: PubMed
    Score: 0.008
  42. Discrimination of benign from malignant breast lesions in dense breasts with model-based analysis of regions-of-interest using directional diffusion-weighted images. BMC Med Imaging. 2020 06 09; 20(1):61.
    View in: PubMed
    Score: 0.008
  43. Patient-Specific Characterization of Breast Cancer Hemodynamics Using Image-Guided Computational Fluid Dynamics. IEEE Trans Med Imaging. 2020 09; 39(9):2760-2771.
    View in: PubMed
    Score: 0.008
  44. Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med. 2019 03; 81(3):2147-2160.
    View in: PubMed
    Score: 0.007
  45. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density. Acad Radiol. 2019 07; 26(7):e141-e149.
    View in: PubMed
    Score: 0.007
  46. A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imaging. 1998 Sep-Oct; 8(5):1126-34.
    View in: PubMed
    Score: 0.007
  47. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
    View in: PubMed
    Score: 0.007
  48. Fast Temporal Resolution Dynamic Contrast-Enhanced MRI: Histogram Analysis Versus Visual Analysis for Differentiating Benign and Malignant Breast Lesions. AJR Am J Roentgenol. 2018 10; 211(4):933-939.
    View in: PubMed
    Score: 0.007
  49. Fast spectroscopic imaging of water and fat resonances to improve the quality of MR images. Acad Radiol. 1998 Apr; 5(4):269-75.
    View in: PubMed
    Score: 0.007
  50. Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation. Int J Radiat Oncol Biol Phys. 1998 Apr 01; 41(1):151-9.
    View in: PubMed
    Score: 0.007
  51. In vivo imaging of extraction fraction of low molecular weight MR contrast agents and perfusion rate in rodent tumors. Magn Reson Med. 1997 Aug; 38(2):259-68.
    View in: PubMed
    Score: 0.006
  52. Spectroscopic imaging of the water resonance with short repetition time to study tumor response to hyperoxia. Magn Reson Med. 1997 Jul; 38(1):27-32.
    View in: PubMed
    Score: 0.006
  53. Value of breast MRI for patients with a biopsy showing atypical ductal hyperplasia (ADH). J Magn Reson Imaging. 2017 12; 46(6):1738-1747.
    View in: PubMed
    Score: 0.006
  54. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.006
  55. Dynamic contrast measurements in rodent model tumors. Acad Radiol. 1996 Aug; 3 Suppl 2:S384-6.
    View in: PubMed
    Score: 0.006
  56. Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. EMBO Rep. 2015 Sep; 16(9):1145-63.
    View in: PubMed
    Score: 0.005
  57. Changes in T2*-weighted images during hyperoxia differentiate tumors from normal tissue. Magn Reson Med. 1995 Mar; 33(3):318-25.
    View in: PubMed
    Score: 0.005
  58. The renin-angiotensin system mediates EGF receptor-vitamin d receptor cross-talk in colitis-associated colon cancer. Clin Cancer Res. 2014 Nov 15; 20(22):5848-5859.
    View in: PubMed
    Score: 0.005
  59. Effects of hyperoxia on T2* and resonance frequency weighted magnetic resonance images of rodent tumours. NMR Biomed. 1994 Mar; 7(1-2):3-11.
    View in: PubMed
    Score: 0.005
  60. Magnetic resonance imaging of rodent tumors using radiofrequency gradient echoes. Magn Reson Imaging. 1994; 12(6):881-93.
    View in: PubMed
    Score: 0.005
  61. MRI of neonatal necrotizing enterocolitis in a rodent model. NMR Biomed. 2014 Mar; 27(3):272-9.
    View in: PubMed
    Score: 0.005
  62. Potential of computer-aided diagnosis of high spectral and spatial resolution (HiSS) MRI in the classification of breast lesions. J Magn Reson Imaging. 2014 Jan; 39(1):59-67.
    View in: PubMed
    Score: 0.005
  63. Comparing post-operative human breast specimen radiograph and MRI in lesion margin and volume assessment. J Appl Clin Med Phys. 2012 Nov 08; 13(6):3802.
    View in: PubMed
    Score: 0.005
  64. Do we really need contrast agents? Eur J Radiol. 2012 Sep; 81 Suppl 1:S99-100.
    View in: PubMed
    Score: 0.004
  65. Safety limitations of MR-HIFU treatment near interfaces: a phantom validation. J Appl Clin Med Phys. 2012 Mar 08; 13(2):3739.
    View in: PubMed
    Score: 0.004
  66. The diverse pathology and kinetics of mass, nonmass, and focus enhancement on MR imaging of the breast. J Magn Reson Imaging. 2011 Jun; 33(6):1382-9.
    View in: PubMed
    Score: 0.004
  67. Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol. 2011 Jul; 21(7):1374-82.
    View in: PubMed
    Score: 0.004
  68. Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med. 2010 Jun; 63(6):1601-9.
    View in: PubMed
    Score: 0.004
  69. Relating dose of contrast media administered to uptake and washout of malignant lesions on DCEMRI of the breast. Acad Radiol. 2010 Jan; 17(1):24-30.
    View in: PubMed
    Score: 0.004
  70. Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrast-enhanced MRI acquisition. AJR Am J Roentgenol. 2009 Sep; 193(3):832-9.
    View in: PubMed
    Score: 0.004
  71. Characterization of response to radiation mediated gene therapy by means of multimodality imaging. Magn Reson Med. 2009 Aug; 62(2):348-56.
    View in: PubMed
    Score: 0.004
  72. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.004
  73. Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn's disease. Acad Radiol. 2009 May; 16(5):597-603.
    View in: PubMed
    Score: 0.004
  74. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.003
  75. DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement? Med Phys. 2008 Jul; 35(7):3102-9.
    View in: PubMed
    Score: 0.003
  76. Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study. Magn Reson Med. 2008 Apr; 59(4):747-54.
    View in: PubMed
    Score: 0.003
  77. Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging. 2007 Jun; 25(5):593-603.
    View in: PubMed
    Score: 0.003
  78. Magnetic resonance imaging of changes in muscle tissues after membrane trauma. Ann N Y Acad Sci. 2005 Dec; 1066:272-85.
    View in: PubMed
    Score: 0.003
  79. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
    View in: PubMed
    Score: 0.003
  80. Differentiating between T1 and T2* changes caused by gadopentetate dimeglumine in the kidney by using a double-echo dynamic MR imaging sequence. J Magn Reson Imaging. 1996 Sep-Oct; 6(5):764-8.
    View in: PubMed
    Score: 0.001
  81. Measurement of differences in pO2 in response to perfluorocarbon/carbogen in FSa and NFSa murine fibrosarcomas with low-frequency electron paramagnetic resonance oximetry. Radiat Res. 1996 May; 145(5):610-8.
    View in: PubMed
    Score: 0.001
  82. Hepatic cancers and their response to chemoembolization therapy. Quantitative image-guided 31P magnetic resonance spectroscopy. Invest Radiol. 1992 Jun; 27(6):456-64.
    View in: PubMed
    Score: 0.001
  83. Image-guided 31P magnetic resonance spectroscopy of normal and transplanted human kidneys. Kidney Int. 1990 Aug; 38(2):294-300.
    View in: PubMed
    Score: 0.001
  84. Non-invasive quantitation of human liver metabolites using image-guided 31P magnetic resonance spectroscopy. NMR Biomed. 1990 Feb; 3(1):17-22.
    View in: PubMed
    Score: 0.001
  85. Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study. Cancer Res. 1989 Apr 15; 49(8):2123-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.